Digestive Diseases and Sciences

, Volume 45, Issue 11, pp 2221–2228 | Cite as

Liver Damage in Hemodialysis Patients with Hepatitis C Virus Viremia: A Prospective 10-Year Study

  • Norihiro Furusyo
  • Jun Hayashi
  • Yoko Kanamoto-Tanaka
  • Iwao Ariyama
  • Yoshitaka Etoh
  • Masaru Shigematsu
  • Seizaburo Kashiwagi
Article

Abstract

Hepatitis C virus (HCV) infection is a major problem associated with hemodialysis. The extent of liver damage in hemodialysis patients with chronic HCV infection has not been thoroughly documented. The aim of this study was to evaluate liver damage of hemodialysis patients infected with HCV. A total of 233 hemodialysis patients were categorized into two groups at entry: group X, 80 positive for serum HCV RNA, and group Y, 153 negative for serum HCV RNA. All were tested for serum alanine aminotransferase (ALT) serially from 1989 to 1998, and serum hyaluronic acid (HA), serum type-IV collagen (IV-C), platelet counts, and ultrasonographic examination of the liver was done in 1998. In group X, 61.3% had continuously abnormal ALT levels for over six months followed by normal ALT levels. Of the group X patients, 11.3% had abnormal ALT levels in 1998, and in three, hepatocellular carcinoma occurred. Mean HA and IV-C levels in group X (648.8 and 188.7 ng/ml, respectively) were significantly higher than in group Y (213.1 and 165.5 ng/ml, respectively) (P < 0.05). Ultrasonographic findings significantly correlated with serum HA level and platelet counts and showed significantly more abnormalities in group X than in group Y (P < 0.05). From these findings, a combined examination with ultrasonography and serum fibrogenesis markers is useful for detection of liver damage in hemodialysis patients with HCV viremia.

hemodialysis hepatitis C virus hyaluronic acid type-IV collagen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Hayashi J, Nakashima K, Kajiyama W, Noguchi A, Morofuji M, Maeda Y, Kashiwagi S: Prevalence of antibody to hepatitis C virus in hemodialysis patients. Am J Epidemiol 134:651–657, 1991Google Scholar
  2. 2.
    Sakamoto N, Enomoto N, Marumo F, Sato C: Prevalence of hepatitis C virus infection among long-term hemodialysis patients: Detection of hepatitis C virus RNA in plasma. J Med Virol 39:11–15, 1993Google Scholar
  3. 3.
    Hayashi J, Yoshimura E, Nabeshima A, Kishihara Y, Ikematsu H, Hirata M, Maeda Y, Kashiwagi S: Seroepidemiology of hepatitis C virus infection in hemodialysis patients and the general population in Fukuoka and Okinawa, Japan. J Gastroenterol 29:276–281, 1994Google Scholar
  4. 4.
    Hayashi J, Nakashima K, Yoshimura E, Kishihara Y, Ohmiya M, Hirata M, Kashiwagi S: Prevalence and role of hepatitis C viraemia in haemodialysis patients in Japan. J Infect 28:271–277, 1994Google Scholar
  5. 5.
    Roth D: Hepatitis C virus: The nephrologist's view. Am J Kidney Dis 25:3–16, 1995Google Scholar
  6. 6.
    van der Poel CL, Cuypers HT, Reesink HW: Hepatitis C virus six years on. Lancet 344:1475–1479, 1994Google Scholar
  7. 7.
    Vitale C, Tricerri A, Marangella M, Vacha GM, Giorcelli G, Marini C, Molinaro G, Cosseddu D, Linari F: Epidemiology of hepatitis C virus infection in dialysis units: First versus second-generation assays. Nephron 64:315–316, 1993Google Scholar
  8. 8.
    Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E, Alberola ML, Alamo C, Galera A, Garron MP, Gonzalez-Parra E, Fernandez de Gabriel MV, Oliva H, Carreno V: Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 22:822–828, 1993Google Scholar
  9. 9.
    Chan TM, Lok AS, Cheng IK, Chan RT: Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays. Hepatology 17:5–8, 1993Google Scholar
  10. 10.
    Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y, Etoh Y, Ikematsu H, Kashiwagi S: Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25:697–701, 1997Google Scholar
  11. 11.
    Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K, Kashiwagi S: Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 90:794–799, 1995Google Scholar
  12. 12.
    Hayashi J, Yoshimura E, Kishihara Y, Yamaji K, Etoh Y, Ikematsu H, Kashiwagi S: Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol 91:314–318, 1996Google Scholar
  13. 13.
    Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi Y: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 73:673–679, 1992Google Scholar
  14. 14.
    Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, Choo QL, Colombo M, Cuypers HTM, Date T, Dusheiko GM, Esteban JI, Fay O, Hadzyannis SJ, Han J, Hatzakis A, Holmes EC, Hotta H, Houghton M, Irwine B, Kohara M, Kolberg JA, Kuo G, Lau JYN, Lelie PN, Maertens G, McOmish F, Miyamura T, Mizokami M, Nomoto A, Prince AM, Reesink HW, Rice C, Roggendorf M, Schalm SW, Shikata T, Shimotohno K, Stuyver L, Trepo C, Weiner A, Yap PL, Urdea MS: A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1324, 1994Google Scholar
  15. 15.
    Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J: Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 31:2679–2682, 1993Google Scholar
  16. 16.
    Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF: Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: A longitudinal study. J Clin Ultrasound 21:303–308, 1993Google Scholar
  17. 17.
    Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A: Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 340:697–698, 1992Google Scholar
  18. 18.
    al-Wakeel J, Malik GH, al-Mohaya S, Mitwalli A, Baroudi F, el Gamal H, Kechrid M: Liver disease in dialysis patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 11:2265–2268, 1996Google Scholar
  19. 19.
    Wolf PL, Williams D, Coplon N, Coulson AS: Low aspartate transaminase activity in serum of patients undergoing hemodialysis. Clin Chem 18:567–568, 1972Google Scholar
  20. 20.
    Warnock LG, Stone WJ, Wagner C: Decreased aspartate transaminase ("SGOT") activity in serum of uremic patients. Clin Chem 20:1213–1216, 1974Google Scholar
  21. 21.
    Cohen GA, Goffinet JA, Donabedian RK, Conn HO: Observations on decreased serum glutamic oxaloacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 84:275–280, 1976Google Scholar
  22. 22.
    Crawford DR, Reyna RS, Weiner MW: Effects on in vivo and in vitro dialysis on plasma transaminase activity. Nephron 22:418–422, 1978Google Scholar
  23. 23.
    Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, Yokozeki K, Kobayashi S, Irie Y: Hypoaminotransferasemia in patients undergoing long-term hemodialysis: Clinical and biochemical appraisal. Gastroenterology 109:1295–1300, 1995Google Scholar
  24. 24.
    Bailey GL, Katz AI, Hampers CL, Merrill JP: Alternations in serum enzymes in chronic renal failure. JAMA 213:2263–2265, 1970Google Scholar
  25. 25.
    Heaf JG: Liver function tests and pyridoxine levels in uremia. Nephron 30:131–136, 1982Google Scholar
  26. 26.
    Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G: Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1:414–416, 1986Google Scholar
  27. 27.
    Ishibashi K, Kashiwagi T, Ito A, Tanaka Y, Nagasawa M, Toyama T, Ozaki S, Naito M, Azuma M: Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Hepatology 24:27–31, 1996Google Scholar
  28. 28.
    Yabu K, Kiyosawa K, Mori H, Matsumoto A, Yoshizawa K, Tanaka E, Furuta S: Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 29:474–479, 1994Google Scholar
  29. 29.
    Kosugi S, Imai Y, Kurata Y, Tomiyama Y, Shiraga M, Honda S, Nishikawa M, Yonezawa T, Kanakura Y, Matsuzawa Y: Platelet-associated IgM elevated in patients with chronic hepatitis C contains no anti-platelet autoantibodies. Liver 17:230–237, 1997Google Scholar
  30. 30.
    Ono K, Uchino F: Formation of amyloid-like substance from beta-2–microglobulin in vitro. Role of serum amyloid P component: A preliminary study. Nephron 66:404–407, 1994Google Scholar
  31. 31.
    Yuki N, Hayashi N, Matsushita Y, Tabata T, Inoue T, Fusamoto H, Kamada T: Hepatitis C biochemical remission and viral replication in haemodialysis patients. J Med Virol 48:242–246, 1996Google Scholar
  32. 32.
    Okuda K, Hayashi H, Yokozeki K, Irie Y: Destruction of hepatitis C virus particles by haemodialysis. Lancet 347:909–910, 1996Google Scholar
  33. 33.
    Hayashi H, Okuda K, Yokosuka O, Kobayashi S, Yokozeki K, Ohtake Y, Irie Y: Adsorption of hepatitis C virus particles onto the dialyzer membrane. Artif Organs 21:1056–1059, 1997Google Scholar
  34. 34.
    Furusyo N, Hayashi J, Ariyama I, Sawayama Y, Etoh Y, Shigematsu M, Kashiwagi S: Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol 95:490–496; 2000Google Scholar
  35. 35.
    DuBois DB, Gretch D, dela Rosa C, Lee W, Fine J, Blagg CR, Corey L: Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: Gender-related differences in viral load. Am J Kidney Dis 24:795–801, 1994Google Scholar
  36. 36.
    Hayashi J, Kawakami Y, Nabeshima A, Kishihara Y, Furusyo N, Sawayama Y, Kinukawa N, Kashiwagi S: Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Dig Dis Sci 43:384–391, 1998Google Scholar
  37. 37.
    Akiba T, Kawaguchi Y, Kuroda M, Nihei H, Hidai H, Yanakawa M, Yamazaki C, Marumoto F: Survey on hepatitis C virus infection in Japanese dialysis population. J Jpn Soc Dial Ther 27:77–82, 1994Google Scholar

Copyright information

© Plenum Publishing Corporation 2000

Authors and Affiliations

  • Norihiro Furusyo
    • 1
    • 2
  • Jun Hayashi
    • 1
    • 2
  • Yoko Kanamoto-Tanaka
    • 1
    • 2
  • Iwao Ariyama
    • 1
    • 2
  • Yoshitaka Etoh
    • 1
    • 2
  • Masaru Shigematsu
    • 1
    • 2
  • Seizaburo Kashiwagi
    • 1
    • 2
  1. 1.Department of General MedicineKyushu University HospitalFukuokaJapan
  2. 2.Shigematsu ClinicFukuokaJapan

Personalised recommendations